Hae Jin Park1, Ah Ram Chang2, Youngseok Seo3, Chul Koo Cho3, Won-Il Jang3, Mi Sook Kim3, Chulwon Choi4. 1. Department of Radiation Oncology, Hanyang University Hospital, Seoul, Republic of Korea. 2. Department of Radiation Oncology, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea CyberKnife Center, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea changaram@schmc.ac.kr. 3. Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea CyberKnife Center, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea. 4. Department of Radiation Oncology, Dongnam Institute of Radiological and Medical Sciences, Busan, Republic of Korea.
Abstract
AIM: To evaluate local control and patient survival for recurrent or oligometastatic uterine cervical cancer treated with stereotactic body radiotherapy (SBRT) using CyberKnife, and to demonstrate the safety of SBRT. PATIENTS AND METHODS: Between 2002 and 2013, 100 recurrent or oligometastatic lesions in 85 patients were treated with SBRT at three Institutions. SBRT sites were within the previous RT field in 59 and partially overlapped in nine. SBRT sites included three local recurrences, 89 lymph node metastases, and eight distant metastases. Patients were treated with a median dose of 39 Gy in three fractions, which was equivalent to a biologically effective dose (BED) of 90 Gy. RESULTS: The median follow-up period was 20.4 months. Local failure occurred in 17 out of 100 SBRT-treated sites. The 2-year and 5-year local progression-free survival rates were 82.5% and 78.8%, respectively. Eleven local failures occurred within the previous RT field. The 2-year and 5-year overall survival rates were 57.5% and 32.9%, respectively. BED >90 Gy (p=0.072) and >69 Gy (p=0.059) and longer disease-free interval (p=0.065) predicted marginally superior local control. Re-irradiation appeared to be related to inferior local control (p<0.001), but the SBRT BED in this group was much lower than the dose in the other group (median BED, 79 Gy vs. 90 Gy). Chronic toxicities of grade 3 or more occurred in five cases. CONCLUSION: SBRT for recurrent or oligometastatic cervical cancer resulted in excellent local control, especially with a long disease-free interval and high BED treatment, with acceptable toxicities. Therefore, SBRT can be considered a therapeutic option for these patients. Copyright
AIM: To evaluate local control and patient survival for recurrent or oligometastatic uterine cervical cancer treated with stereotactic body radiotherapy (SBRT) using CyberKnife, and to demonstrate the safety of SBRT. PATIENTS AND METHODS: Between 2002 and 2013, 100 recurrent or oligometastatic lesions in 85 patients were treated with SBRT at three Institutions. SBRT sites were within the previous RT field in 59 and partially overlapped in nine. SBRT sites included three local recurrences, 89 lymph node metastases, and eight distant metastases. Patients were treated with a median dose of 39 Gy in three fractions, which was equivalent to a biologically effective dose (BED) of 90 Gy. RESULTS: The median follow-up period was 20.4 months. Local failure occurred in 17 out of 100 SBRT-treated sites. The 2-year and 5-year local progression-free survival rates were 82.5% and 78.8%, respectively. Eleven local failures occurred within the previous RT field. The 2-year and 5-year overall survival rates were 57.5% and 32.9%, respectively. BED >90 Gy (p=0.072) and >69 Gy (p=0.059) and longer disease-free interval (p=0.065) predicted marginally superior local control. Re-irradiation appeared to be related to inferior local control (p<0.001), but the SBRT BED in this group was much lower than the dose in the other group (median BED, 79 Gy vs. 90 Gy). Chronic toxicities of grade 3 or more occurred in five cases. CONCLUSION: SBRT for recurrent or oligometastatic cervical cancer resulted in excellent local control, especially with a long disease-free interval and high BED treatment, with acceptable toxicities. Therefore, SBRT can be considered a therapeutic option for these patients. Copyright
Authors: E Leung; A Gladwish; A Sahgal; S S Lo; C A Kunos; R M Lanciano; C A Mantz; M Guckenberger; T M Zagar; N A Mayr; A R Chang; S Jorcano; T Biswas; A Pontoriero; K V Albuquerque Journal: Radiat Oncol Date: 2020-01-30 Impact factor: 3.481
Authors: Dennis Winkel; Gijsbert H Bol; Anita M Werensteijn-Honingh; Ilse H Kiekebosch; Bram van Asselen; Martijn P W Intven; Wietse S C Eppinga; Bas W Raaymakers; Ina M Jürgenliemk-Schulz; Petra S Kroon Journal: Phys Imaging Radiat Oncol Date: 2019-03-01